Clobetasol

Basic clobetasol information

• INN (international nonproprietary name): Clobetasol (as clobetasol propionate).
• Brand names available in the United Kingdom: Dermovate (0.05% cream, ointment and scalp application), Clobex and Etrivex (500 micrograms/g shampoo).
• ATC code: D07AD01 (corticosteroids, very potent, group IV; for dermatological use).
• Forms and strengths: cream 0.05% (500 micrograms/g); ointment 0.05%; scalp application and shampoo 0.05% (500 micrograms/g).
• Manufacturers in the United Kingdom: GlaxoSmithKline (GSK) and Galderma; generic versions are also available.
• Registration status in the United Kingdom: Licensed by the MHRA; packaged and labelled according to MHRA requirements.
• OTC / Rx classification: Prescription-only (Rx) in the United Kingdom.

Legal status and availability in the UK

In our online pharmacy, clobetasol is available on prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Wondering how quickly clobetasol works when prescribed in NHS practice?

In UK dermatology pathways clobetasol is reserved as a very‑potent topical corticosteroid for resistant plaque psoriasis, severe atopic or contact dermatitis flares, lichen planus and discoid lupus.

Product information and NHS guidance recommend applying a thin layer twice daily for 2–4 weeks for many indications and not exceeding 50 g per week.

Patients commonly report fast symptomatic relief such as reduced itch and erythema within days of starting an appropriate topical steroid regimen.

Sustained remission frequently requires stepping down to lower‑potency maintenance therapy or introducing steroid‑sparing agents under specialist supervision.

Electronic prescribing and NHS shared records such as EPS support monitoring and limit inappropriate long‑term repeat supply.

Community pharmacists routinely counsel patients about correct application technique, avoiding occlusion and duration limits.

Indications and expanded uses

Not sure when clobetasol is the right choice?

Licensed UK indications cover severe inflammatory dermatoses not controlled by lower‑potency topical steroids.

Typical regimens from product information per condition are: psoriasis non‑facial thin layer BID for 2–4 weeks, atopic/contact dermatitis up to 2 weeks, lichen planus BID 2–4 weeks and discoid lupus BID 2–8 weeks.

Off‑label specialist uses happen within dermatology clinics and may include temporising regimens for nail fold disease or focal hypertrophic lesions with explicit informed consent and monitoring.

Strong cautions are given against facial, perioral and intertriginous application because these sites absorb more drug and are prone to atrophy.

• Approved indications: Severe plaque psoriasis, severe atopic/contact dermatitis flares, lichen planus, discoid lupus.
• Typical regimen: Thin layer applied twice daily; reassess at end of recommended course.
• Off‑label examples: Nail fold inflammation, focal hypertrophic lesions under specialist care.
• Monitoring needs: Review if no improvement; watch for skin atrophy and signs of adrenal suppression with large‑area treatment.

Composition and brand landscape

Curious which brands and forms are supplied in the UK?

Clobetasol propionate is supplied in the UK as Dermovate, Clobex and Etrivex.

Most UK products are at 0.05% strength, expressed as 500 micrograms per gram in creams, ointments and shampoos.

Available forms include 0.05% creams, 0.05% ointments and scalp preparations such as scalp applications and shampoos at 500 micrograms/g.

Manufacturers include GlaxoSmithKline and Galderma, and generic versions are also available.

Contraindications and special precautions

Worried about who must avoid clobetasol?

Absolute contraindications listed in product information include untreated bacterial, viral or fungal skin infections and known hypersensitivity to clobetasol or other corticosteroids.

Clobetasol must not be used for rosacea, acne vulgaris or perioral dermatitis and should not be applied with occlusive dressings on large areas or used long‑term in children.

Relative cautions include the elderly because of higher atrophy risk, people with diabetes due to possible glycaemic effects if systemic absorption occurs, and patients with extensive psoriasis where systemic toxicity risk is raised.

Pregnancy and lactation are not absolute contraindications but product guidance recommends use only if clearly needed and under supervision.

• Contraindication — reason: Untreated skin infection — Risk of worsening infection and delayed healing.
• Contraindication — reason: Hypersensitivity to corticosteroids — Risk of allergic reaction.
• Contraindication — reason: Rosacea or perioral dermatitis — Steroids may worsen these conditions.
• Contraindication — reason: Use with large‑area occlusion in children — Risk of systemic absorption and HPA suppression.

Suspected adverse reactions should be reported via the MHRA Yellow Card scheme.

Dosage guidelines

Need clear dosing instructions to explain to patients?

Standard NHS dosing follows the product information: apply a thin layer of 0.05% clobetasol cream or ointment twice daily for most indications and follow specific scalp product instructions as labelled.

Typical durations are 2–4 weeks for psoriasis and lichen planus, up to 2 weeks for atopic/contact dermatitis and up to 8 weeks occasionally for discoid lupus with specialist review.

The manufacturer guidance sets a typical maximum weekly topical use of not more than 50 g per week.

Paediatric use is restricted to specialist prescription and generally avoided in children under 12 unless explicitly indicated.

Counselling points include missed dose advice — apply as soon as remembered but do not double the next dose — and overdose guidance to stop use and seek medical review if excessive application has occurred.

Interactions overview

Worried about interactions if you take other medicines?

Topical clobetasol has limited direct pharmacokinetic interactions when used as directed because systemic absorption is minimal for small‑area treatments.

Interaction concerns arise if systemic absorption occurs, such as from prolonged use, application to large areas, mucosal use or occlusion.

Potential interaction scenarios include additive HPA axis suppression when topical and systemic corticosteroids are combined and altered glucose control in people taking drugs affecting glucose tolerance.

Potent CYP3A4 inhibitors could theoretically increase systemic steroid exposure in rare cases of systemic absorption, so pharmacovigilance is advised.

• Check for concurrent systemic corticosteroids — risk of additive HPA suppression.
• Review antidiabetic medications — absorbed steroid may worsen glycaemic control in susceptible patients.
• Assess co‑medication with strong CYP3A4 inhibitors in cases of extensive topical use.

Report any systemic corticosteroid signs such as unexplained weight gain or facial rounding to a clinician and the MHRA if suspected as an adverse reaction.

Comparable medicines and preferences

Trying to choose between powerful topical steroids?

Comparable potent topical corticosteroids include betamethasone dipropionate, which may be considered where appropriate.

Clobetasol’s advantages are its rapid and potent anti‑inflammatory effect and availability in multiple formulations that suit different sites such as scalp foams and shampoos.

Disadvantages include a higher risk of local atrophy, striae and telangiectasia when used long term or inappropriately, and a greater potential for systemic effects if misused.

NHS prescribing typically follows a stepwise approach: medium‑potency steroids first and reserving clobetasol for refractory or severe flares.

• Efficacy — Very potent and effective for short rescue courses.
• Safety profile — Significant local side effects with prolonged use; monitor closely.
• Suitability by site — Avoid thin‑skinned areas; use scalp formulations for hair‑bearing sites.
• Patient factors — Use caution in children, elderly and people with comorbidities such as diabetes.

For recurrent disease consider steroid‑sparing alternatives such as topical calcineurin inhibitors or referral for systemic or biological therapies where indicated.

Frequently asked questions

Can I use clobetasol on my face?

No — avoid facial, eyelid or groin use due to thin skin and higher absorption risk.

How long can I use it?

Typical NHS guidance is 2–4 weeks for many conditions; do not exceed product maximums and avoid more than 50 g per week without review.

What if I miss an application?

Apply as soon as you remember but do not double the next dose.

Is it safe in children?

Only with strict medical supervision; generally avoid in children under 12 unless prescribed by a specialist.

Report suspected adverse effects to the MHRA Yellow Card scheme and consult a GP, community pharmacist or dermatology clinic for persistent symptoms.

Guidelines for proper use

Want a short checklist to give patients at the counter?

Pharmacist counselling should cover the indication, correct application (thin layer rubbed in gently), frequency (usually BID) and duration limits (2–4 weeks for many conditions).

Emphasise the weekly maximum — do not exceed 50 g per week — and avoid occlusive dressings unless explicitly instructed by a clinician.

Advise storage below 30°C, protection from light, keeping out of reach of children and not freezing emulsions or shampoos.

Show patients how to apply a pea‑to‑bean sized amount to a small lesion and explain the need to stop and seek review if increased local irritation, skin thinning, striae or systemic signs occur.

Direct patients to NHS patient portals, pharmacy first services and local dermatology referral pathways for ongoing care.

Recommend reporting adverse reactions to the MHRA Yellow Card scheme.

Patient information summary:

• Medicine: Clobetasol propionate 0.05%.
• How to use: Thin layer twice daily to affected area for prescribed duration.
• Storage: Store below 30°C and keep away from children.
• Warnings: Avoid face, groin, and occlusion; report side effects via MHRA Yellow Card.

Delivery across the United Kingdom